
Octahydroaminoacridine Succinate Approved in China for Alzheimer’s Disease, Marking Progress in Innovative Drug Development
On June 25, 2026, the National Medical Products Administration (NMPA) announced Octahydroaminoacridine Succinate approved in…

On June 25, 2026, the National Medical Products Administration (NMPA) announced Octahydroaminoacridine Succinate approved in…

Ovarian cancer drugs in China mainly include five categories: PARP inhibitors, anti-angiogenic therapies, antibody-drug conjugates…

Epidermal growth factor receptor EGFR–targeted drugs represent a cornerstone in the treatment of advanced non–small…

DengYueMed is a licensed Pharmaceutical Distributor in Hong Kong providing wholesale pharmaceuticals, global drug export,…

What are the treatment options for Duchenne muscular dystrophy? Current treatment options for Duchenne muscular…

On July 9, 2026, China officially released the China National Essential Medicines List 2026, adding…

How to find the latest breast cancer drugs begins with knowing your breast cancer subtype…

The top 5 rare disease companies include Roche, Novartis, Johnson & Johnson, AstraZeneca, and Vertex…

Abbisko’s Pimicotinib for tenosynovial giant cell tumor (TGCT) is an oral CSF-1R inhibitor developed by…

How do pharmaceutical wholesalers work? Pharmaceutical wholesalers source medicines from approved suppliers, manage quality control…